FLT3 and acute myeloid leukemia: TP53 mutations have been reported mutually exclusive with NPM1 mutation and FLT3–ITD,43, 44, 45 underscoring the probability for AVA sensitivity in AML patients with NPM1 and FLT3–ITD.